spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Healthcare Industry News:  Celebrex 

Biopharmaceuticals Generics Litigation

 News Release - March 7, 2008

Pfizer Wins Challenge to Two Main U.S. Patents for Celebrex by Generic Manufacturer Teva

NEW YORK--(HSMN NewsFeed)--Pfizer Inc announced today that the Court of Appeals for the Federal Circuit has upheld the two main U.S. patents covering Celebrex, the company’s selective non-steroidal anti-inflammatory (NSAID) medicine used to treat pain and inflammation. The patents had been challenged by generic manufacturer Teva Pharmaceuticals USA.

The panel ruled that the patents (Nos. 5,466,823 and 5,563,165) covering the active ingredient and a pharmaceutical composition thereof are valid, enforceable and infringed by the generic manufacturer’s product. In the same decision, the Court ruled that a third patent (No. 5,760,068) covering the use in the treatment of inflammation was invalid. The decision prohibits Teva from launching a competitor drug in the U.S. until May 2014. Either party may request a rehearing by the Court of Appeals or a review by the U.S. Supreme Court. Celebrex was approved by the FDA in 1998. Its sales totaled $1.7 billion the U.S. in 2007.

Source: Pfizer

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

Search: Pfizer 
Search: Celebrex 
Search: Teva Pharmaceuticals 
Healthcare Industry NewsFeed  


FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.